Deciphera Pharmaceuticals (DCPH) Stock Analysis

What Deciphera Pharmaceuticals does

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapies to significantly improve outcomes for cancer patients. Their core strategy involves tackling the mechanisms of drug resistance that often limit the effectiveness and longevity of current cancer treatments, serving markets both domestically and internationally. The company's flagship product, QINLOCK, is employed in the treatment of gastrointestinal stromal tumors (GIST) and is additionally undergoing a Phase 3 clinical trial (INTRIGUE study) for second-line GIST. Deciphera's pipeline also includes vimseltinib, a potent, orally available, and highly selective switch-control kinase inhibitor targeting colony stimulating factor 1 receptor (CSF1R) for tenosynovial giant cell tumor (TGCT). Furthermore, they are advancing DCC-3116, currently in preclinical development, which targets RAS/RAF mutant cancers. Established in 2003, Deciphera Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Key metrics

ETFs linked to DCPH

Broad-market and Healthcare sector ETFs an investor holding Deciphera Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how DCPH fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals trades under the ticker DCPH on NASDAQ.

Which exchange is DCPH listed on?

DCPH is listed on NASDAQ.

What sector does Deciphera Pharmaceuticals operate in?

Deciphera Pharmaceuticals is classified in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).

How can PortView help analyze DCPH in a portfolio?

PortView shows DCPH's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.